ArticleLiver cancer2022

Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial.

Daneng Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.